DUBLIN – Zelluna Immunotherapy AS is the latest contender to throw its hat into the immuno-oncology ring, but the Oslo, Norway-based startup can draw on several decades' worth of clinical research in its effort to build a pipeline of cell and biologic therapies based on proprietary T-cell receptors (TCRs) against important tumor antigens.